ArticleDigestive diseases and sciences2024

Real-World Outcomes of Patients Starting Intravenous and Transitioning to Subcutaneous Vedolizumab in Inflammatory Bowel Disease.

N Lamichhane et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.